Scholarlink

<p>There is growing recognition of drug-induced inflammatory colitis due to increasing availability of novel therapies. This review provides an overview of contemporary drug classes causing inflammatory colitis, excluding immune checkpoint inhibitor-induced colitis which has previously been well characterised. We report on the mechanism, frequency, clinical presentation, endoscopic appearance and histopathological findings of inflammatory colitis secondary to tyrosine kinase inhibitors, phosphatidylinositol 3-kinase inhibitors, anti-IL-6 agents, IL-17 inhibitors and anti-CD20 monoclonal antibodies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Drug-induced inflammatory colitis: a review of novel agents

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月3日

查看全文
  • M. Terlato,
  • S. Dimovski,
  • M. Burkhardt,
  • F. Shahshahani,
  • J. P. Segal

摘要

There is growing recognition of drug-induced inflammatory colitis due to increasing availability of novel therapies. This review provides an overview of contemporary drug classes causing inflammatory colitis, excluding immune checkpoint inhibitor-induced colitis which has previously been well characterised. We report on the mechanism, frequency, clinical presentation, endoscopic appearance and histopathological findings of inflammatory colitis secondary to tyrosine kinase inhibitors, phosphatidylinositol 3-kinase inhibitors, anti-IL-6 agents, IL-17 inhibitors and anti-CD20 monoclonal antibodies.